Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.
2016
Purpose Resistance to
bevacizumab(BEV) in
glioblastomais believed to occur via activation of molecular networks including the mTOR/PI3K pathway. Using an MR/PET
molecular imagingbiomarker approach, we investigated the response to combining BEV with the mTOR/PI3K inhibitor BEZ235.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
-
Machine Reading By IdeaReader
32
References
12
Citations
NaN
KQI